🇺🇸 levothyroxin in United States

6,764 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 1,122 reports (16.59%)
  2. Diarrhoea — 863 reports (12.76%)
  3. Nausea — 856 reports (12.66%)
  4. Drug Ineffective — 603 reports (8.91%)
  5. Death — 602 reports (8.9%)
  6. Dyspnoea — 572 reports (8.46%)
  7. Headache — 561 reports (8.29%)
  8. Pain — 551 reports (8.15%)
  9. Dizziness — 535 reports (7.91%)
  10. Fall — 499 reports (7.38%)

Source database →

levothyroxin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is levothyroxin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for levothyroxin in United States?

Ain Shams University is the originator. The local marketing authorisation holder may differ — check the official source linked above.